Award Number:  W81XWH-04-1-0433

TITLE:  Breast Cancer Cell Selective Apoptosis Induced by the Novel Activity of an IL-10 Related Cytokine

PRINCIPAL INVESTIGATOR:  Moira Sauane

CONTRACTING ORGANIZATION:  Columbia University
                                      New York, New York  10032

REPORT DATE:  May 2005

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
                                      Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT:  Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Breast Cancer Cell Selective Apoptosis Induced by the Novel Activity of an IL-10 Related Cytokine

Moira Sauane

Columbia University
New York, New York 10032

E-Mail: Ms2280@columbia.edu

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for Public Release; Distribution Unlimited

Preliminary data document that signaling events leading to Ad.mda-7-induced transformed-cell specific apoptosis are tyrosine kinase-independent. These results suggest that mda-7/IL-24 cancer cell-specific activity could occur through mechanisms independent of binding to its currently recognized cognate receptors and might even occur independent of receptor function. An adenovirus vector expressing a non-secreted version of MDA-7/IL-24 protein was generated via deletion of its signal peptide. This non-secreted protein was as effective as wild-type secreted MDA-7/IL-24 in inducing apoptosis in cancer cell lines, and displayed transformed cell specificity and localization of MDA-7/IL-24 in the Golgi/ER compartments. Based on localization as well as signal transduction pathway activation, MDA-7/IL-24 protein appears to induce ER stress that in turn induces proapoptotic events. A new reagent was generated i.e. a bacterially expressed and purified GST-MDA-7 fusion protein. We describe the properties and characteristics of this protein in this report. Treatment of breast cancer cell lines with GST-MDA-7 sensitizes both wild-type and mutant p53 expressing tumor cells to growth inhibitory and antisurvival effects of ionizing radiation. Our results indicate that mda-7/IL-24-mediated apoptosis can be triggered efficiently in the absence of protein secretion and is likely mediated by ER stress. In addition, retention of tumor-specific activity of GST-MDA-7 suggests that this new reagent may also have therapeutic applications and prove to be a useful experimental tool.

Mda-7, IL-24, ER stress, signal peptide

Unclassified

Unclassified

Unclassified

Unclassified

35

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. 239-18
298-102
Table of Contents

Cover ...................................................................................................................... 1
SF 298 .................................................................................................................. 2
Table of Contents ............................................................................................... 3
Introduction .......................................................................................................... 4
Body ..................................................................................................................... 5
Key Research Accomplishments ......................................................................... 14
Reportable Outcomes ......................................................................................... 15
Conclusions .......................................................................................................... 16
References ........................................................................................................... 17
Appendices .......................................................................................................... 18
INTRODUCTION

The objective of the proposed studies focuses on the characterization of a novel tumor cell apoptosis-inducing gene that was identified through the use of subtraction hybridization from human melanoma cells induced to growth arrest and terminally differentiate by treatment with interferon and mezerien. Since expression of this gene correlates with induction of irreversible growth arrest; cancer reversion and terminal differentiation in human melanoma cells it was named melanoma differentiation associated gene-7 (mda-7). Additional studies by our group have confirmed its potential gene therapeutic potential in other cancers, including human breast and prostate cancer-derived cells. The elucidation of the mechanistic basis of its selective action will provide valuable insights into ensuring safe use, improving efficacy, suggest potential pharmacological adjuvants or substitutes and possibly give important additional information for developing improved treatment options. Growth suppression and apoptosis was observed when mda-7/IL-24 was transfected or transduced into a wide spectrum of human breast cancer cell lines. In contrast, no significant growth inhibitory effect was apparent when this gene was transduced into normal breast human epithelial, endothelial, melanocyte, astrocytes or fibroblast cells. This property of mda-7/IL-24 suggests it may have translational potential for the gene-based therapy of breast cancer. Moreover, based on pre-clinical cell culture and animal modeling studies, successful Phase I trials have been performed and a Phase II clinical trial has been recently initiated. MDA-7/IL-24 has been delivered to cells, tumor xenografts and patients in clinical trials via a nonreplicating adenovirus (Ad.mda-7). These studies are contributing greatly to our understanding of the underlying basis of mda-7/IL-24 activity and offers potential for identifying strategies for using small molecule mimetics having equivalent or more potent activity than Ad.mda-7. We previously demonstrated that mda-7/IL-24 cancer cell-specific activity could occur through mechanisms independent of binding to its currently recognized cognate receptors and might even occur independent of receptor function. The present studies were designed to assess whether the potent proapoptotic activity observed with Ad.mda-7 is due to the intracellular or the secreted MDA-7/IL-24 protein. We show that Ad.mda-7 infection of cancer cells results in activation of ER-stress. We demonstrate that mda-7/IL-24-mediated apoptosis can be triggered through a intracellular mechanism (via deletion of the signal peptide of mda-7/IL-24 sequence) and can occur efficiently in the absence of protein secretion. Also, we report the properties and characteristics of a bacterially expressed and purified GST-MDA-7 fusion protein.

We have shown both by biochemical as well as genetic mutation based criteria that activation of STAT1 and STAT3 by mda-7/IL-24 was not essential for the apoptosis triggering activity of the molecule (2). Based on that finding, we set out to define the functional domains of mda-7 and to determine if the apoptotic effect is triggered by intracellular protein, possibly by receptor-independent mechanisms. To this end, an adenovirus vector was constructed that expressed a non-secreted version of mda-7/IL-24 lacking the signal peptide (Ad.SP mda-7) (3). The extent and modality of killing was compared between the full-length mda-7/IL-24 expressing virus (4) and Ad.SP mda-7, the results obtained indicated that the effect of Ad.SP mda-7 and Ad.mda-7 infection was similar with respect to transformed cell apoptosis induction (2) (Fig. 1). MDA-7/IL-24 protein was shown to localize to the ER (5)/Golgi compartments (Fig. 2).

Our results and recent studies by others clearly reveal that intracellular MDA-7/IL-24 protein is active in inducing transformed cell-specific apoptosis, probably through mechanism involving pathway associated with ER-stress. ER stress is caused by different conditions that perturb ER function. In the particular case of ER-stress caused by misfolded protein accumulation, a highly conserved unfolded protein response (6) signal transduction pathway is activated (5). The UPR is characterized by the coordinated activation of multiple signal transduction pathways that lead to the suppression of the initiation step of protein synthesis, and trigger the expression of genes encoding ER chaperones, enzymes and structural components of the ER. Prolonged activation of this pathway leads ultimately to apoptosis. Earlier findings from our group support this hypothesis since induction of the GADD genes is classically associated with the stress response including ER-stress pathways. Induction of GADD genes and further upstream events such as activation of p38MAPK were shown to be induced by mda-7/IL-24 in a transformed cell-specific manner (3, 7). Treatment with Ad.mda-7 also specifically activated the p44/42MAPK pathway (3, 8). Furthermore, Ad.mda-7 infection produced an up-regulation of the inositol 1,4,5-trisphosphate receptor (IP3R) in H1299 cells (9). IP3R is an intracellular calcium-release channel implicated in apoptosis and localized in the ER. BiP has been best characterized for its role in protein folding and assembly, and its up-regulation during ER stress is a hallmark of the unfolded protein response (UPR) (10). Earlier reports identified putative conserved functional HSP70-like chaperone (BiP)-binding sites in both the helix C and F motifs of MDA-7/IL-24 (11). Interestingly, a microarray study was reported showing that mda-7 is able to induce the expression of ER-stress response genes such as BiP (12). Thus an important functional domain mutant, Ad.SP mda-7 was generated and characterized in this funding period. Biochemical studies with this mutant demonstrated the importance of the ER/UPR response in mda-7/IL-24 activity resulting in a high impact publication (3). This work has defined other relevant mutagenesis targets, which will be analyzed in year 2.
Task 2. Identify and characterize MDA-7 binding proteins and interacting molecules by generation of a bacterially expressed soluble MDA-7 protein as a GST fusion. Publication: Sauane et. al., Oncogene 23, 7679–7690 (2004)

I have initiated Task 2 since progress in this area progressed well for technical reasons. I report for year 1 my findings relating to the properties and characteristics of a bacterially expressed and purified GST-MDA-7 fusion protein. Recent data indicates that GST has high transduction efficiency in various cell types and can be used successfully for intracellular delivery of biologically active peptides (13). A GST-MDA-7 fusion protein was expressed and purified from a bacterial expression system to identify and characterize MDA-7 binding proteins and interacting molecules. In the course of these experiments, analysis was also performed to determine if this purified protein had biological activity.

In the context of tumor cell killing, my current recently published findings indicate that bacterially expressed and purified GST-MDA-7 operates in a similar way as does plasmid or adenovirus expressed MDA-7/IL-24 i.e. via JAK/STAT-independent and MAPK-dependent pathways (Figures 3 and 4) (2, 7). Furthermore, treatment with GST-MOB-5 (rat orthologue of mda-7 having ~80% homology (Wang, 2002 #22), purified under the same conditions, did not induce cytotoxic effects in cells and was comparable to treatment with GST protein, indicating that the observed apoptotic effects are not attributed to the novel modifications of the fusion protein but rather are likely a consequence of the activity of the MDA-7/IL-24 moiety of the fusion. The GST-tag might, however, contribute to stability as well as facilitation of protein uptake by cells. There is also a possibility that the uptake process is receptor mediated but the likelihood of currently recognized cognate mda-7/IL-24 receptor participation in this process is not very strong. In general, the data shown here indicates that GST-MDA-7 is functionally equivalent to native MDA-7/IL-24 protein with respect to its tumor-killing attributes. Cancer gene therapy using Ad.mda-7 has significant promise and based on initial successes continues to be evaluated in Phase I/II clinical trials (4, 6). The potential use of GST-MDA-7 protein as a therapeutic is intriguing, since it can enlarge the existing MDA-7/IL-24 therapeutic scope to cover tumors resistant to or uninjectable by Ad.mda-7. Additional work has demonstrated that both Ad.mda-7 as well as the GST-MDA-7 fusion protein radiosensitize primary human glioblastoma cells to comparable extents (8, 14). As shown in Figure 5, GST-MDA-7, but not GST, induced a dose-dependent decrease in viability in MDA-MB-231 cells as reflected by MTT assay. MDA-MB-231 cells were treated with bacterially synthesized GST-MDA-7 followed by exposure to ionizing radiation. GST-MDA-7 suppressed MDA-MB-231 cell growth that was enhanced in a greater than an additive fashion by ionizing radiation. The direct growth inhibitory effect of purified protein in additional breast cancer cells was observed when MCF-7, T47D and MDA-MB-157 breast tumor cells were treated with the GST-MDA-7 protein. In contrast, no significant change in viability or growth was observed following treatment of the normal HBL-100 breast epithelial cell lines with GST-MDA-7. When analyzed with anti-GST antibody, both control GST protein as well as GST-MDA-7 is visualized inside cells in extra-nuclear locations. Samples processed in parallel but reacted with anti-MDA-7 antibody show an intracellular localization of GST-MDA-7 protein. Specificity is demonstrated due to lack of detection of protein in GST treated samples reacted with anti-MDA-7 antibody. It therefore appears that cells internalize
GST as well as GST-MDA-7 fusion proteins. It is unclear if this is a receptor-mediated process, although a more likely possibility is that the GST moiety facilitates uptake of protein by cells as recently reported (13). Thus in year 1, I have been able to standardize expression and purification conditions, produce and biochemically characterize a novel reagent that might have potential therapeutic potential as well as serve as an important research tool. My initial findings have been published in a high impact journal Oncogene (15) and further work in subsequent years will follow up on these initial findings.

figure 2
Fig. 1 Comparative growth inhibition, apoptosis induction and MDA-7 expression in cells infected with Ad. vec, Ad.mda-7, and Ad.SP mda-7. A) Growth inhibition in prostate cell lines: Cells were infected with 100 pfu/cell of Ad.vec, Ad.SP mda-7 or Ad.mda-7 and cell viability was determined by the MTT proliferation assay 5-days after infection. Numbers represent a ratio of specific treatments indicated versus untreated cells. An average of three independent experiments is shown ± S.D. B) MDA-7/IL-24 expression in DU-145 cells: Protein lysates were collected from uninfected (control) DU-145 cells and after infection with Ad.vec, Ad.mda-7 or Ad.SP mda-7. Samples (50 mg) were run on 12% SDS-PAGE, transferred to a nitrocellulose membrane and stained with rabbit anti-mda-7/IL-24 antibody as described in Materials and methods.

Fig. 2 Localization of the MDA-7 protein after infection with Ad.SP mda-7 or Ad.mda-7: MDA-7 protein localization was analyzed by indirect immunofluorescence after infection of DU-145 or P69 cells with 100 pfu/cell of Ad.SP mda-7, Ad.mda-7, or Ad.vec and 48 h post infection cells were fixed and MDA-7/IL-24 protein was detected by indirect immunofluorescence using anti-mda-7/IL-24 antibody. Images of Golgi, ER and mitochondria were obtained using anti-G130, anti-calreticulin, and MitoTracker, respectively, as described in Materials and methods. Images of the different compartments and mda-7/IL-24 were merged. Similar localization of MDA-7/IL-24 protein was observed following infection with the different viruses in P69 cells (data not shown).

Fig. 3 Apoptosis induction by GST-MDA-7 in JAK/STAT deficient human fibrosarcoma cell lines: The indicated cell types were treated with GST or GST-MDA-7 protein. Cells were analyzed for cell viability by MTT assay 5-days later. MTT absorbance of untreated control cells was set at 1 to determine relative number of viable cells. Results are the average of three independent experiments ± S.D.

Fig. 4 Comparative growth inhibition and apoptosis induction in pancreatic cancer cells treated with GST or GST-MDA-7. Cells were treated with GST or GST-MDA-7 and cell viability was determined by the MTT proliferation assay 5-days later. Numbers represent a ratio of specific treatments versus untreated cells. An average of three independent experiments is shown ± S.D.

Fig. 5 Enhanced radiation-induced cell killing in breast cancer cells treated with GST-MDA-7. A) MDA-MB-231 Cells were treated with GST or GST-MDA-7 and cell viability was determined by the MTT proliferation assay 5-days later. Numbers represent a ratio of specific treatments indicated versus untreated cells. B) MDA-MB-231 cells were treated with GST-MDA-7 or GST and 24h after, cells were irradiated (3, 6, 9 Gy). Cells were collected 96 h after irradiation and viability was determined by MTT assay. C) HBL-100, MDA-MB-157, MDA-MB-231, T47D, and MCF-7 were treated with GST or GST-MDA-7 and cell viability was determined by the MTT proliferation assay 5-days later. Numbers represent a ratio of specific treatments indicated versus untreated cells. An average of three independent experiments is shown ± S.D.
Key Research Accomplishments

- I have been able to demonstrate that intracellular localization to the endoplasmic reticulum (ER) is necessary and sufficient for *mda-7/IL-24*-mediated apoptosis. This unprecedented mode of activity of *mda-7/IL-24*, in the context of its belonging to and displaying all the characteristics of a secreted cytokine, serves to highlight the mechanistic basis of its anti-tumor cell activity. Specifically, we have demonstrated that *mda-7/IL-24* is able to trigger ER-stress probably due to binding to BiP. This was accomplished by using an adenovirus vector expressing a nonsecreted version of MDA-7/IL-24 protein generated via deletion of its signal peptide.

- I have been able to standardize expression and purification conditions, produce and biochemically characterize a novel reagent that might have potential therapeutic potential as well as serve as an important research tool. GST-MDA-7 retains its cancer-selective apoptosis-inducing properties, thereby providing a new reagent that will assist in defining the mechanism of action of this novel protein. In addition, retention of tumor-specific activity of GST-MDA-7 suggests that this protein may also have therapeutic applications.
Reportable Outcomes:


Conclusions

I have been able to demonstrate that signaling events leading to susceptibility to Ad.mda-7 or Ad.SP mda-7-induced apoptosis have a potent intracellular mode of action and that this molecule is active in inducing transformed cell-specific apoptosis even without secretion. Our results also demonstrate that mda-7/IL-24 is able to trigger ER-stress.

I have demonstrated that purified recombinant GST-MDA-7 protein recapitulates the potent tumor suppressing and apoptosis-inducing properties of adenovirally expressed mda-7/IL-24 in breast cancer cells. We thereby provide a new reagent that will assist in defining the mechanism of action of this novel cytokine. In addition, retention of tumor specific activity of GST-MDA-7 suggests that this protein may also have therapeutic applications.
References

Melanoma Differentiation Associated Gene-7/Interleukin-24 Promotes Tumor Cell-Specific Apoptosis through Both Secretory and Nonsecretory Pathways

Moira Sautane,1 Irina V. Lebedeva,1 Zuo-zhong Su,1 Heng-tong Choo,1 Aaron Randolph,4 Kristoffer Valerie,4 Paul Dent,2 Rahul V. Gopalakrishnan,1,3 and Paul B. Fisher1,3,5

1Departments of Pathology, 2Urology, and 3Neurosurgery, Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, and 4Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia

Abstract

Melanoma differentiation associated gene-7 (mda-7/IL-24), a novel member of the IL-10 family of cytokines, uniquely displays cancer-specific apoptosis-inducing activity. Positive results in ongoing phase I/II clinical trials have strengthened the possibility of its utilization as a cancer gene therapeutic. Previous studies document that signaling events leading to Ad.mda-7/IL-24-transformed cell apoptosis are tyrosine kinase-independent. These results suggest that mda-7/IL-24 cancer cell-specific activity could occur through mechanisms independent of binding to its currently recognized cognate receptors and might even occur independent of receptor function. An adenosine vector expressing a nonsecreted version of MDA-7/IL-24 protein was generated via deletion of its signal peptide. This nonsecreted protein was as effective as wild-type secreted MDA-7/IL-24 in inducing apoptosis in prostate carcinoma cell lines and displayed transformed cell specificity and localization of MDA-7/IL-24 in the Golgi/endoplasmic reticulum compartments. Our results indicate that mda-7/IL-24-mediated apoptosis can be triggered through a combination of intracellular as well as secretory mechanisms and can occur efficiently in the absence of protein secretion.

Introduction

Melanoma differentiation associated gene-7 (mda-7) was identified by subtraction hybridization in the context of induction of irreversible growth arrest and terminal differentiation of human melanoma cells (1, 2). Transfection of mda-7 into a spectrum of human and rodent tumor cells confirmed potent growth-inhibitory properties, not only in the context of melanoma but also in diverse human cancers (3). In contrast, this antitumor effect was not apparent in normal cells (3). Structural and sequence homology in addition to functional conservation indicated that this gene belongs to the interleukin (IL)-10 family of cytokines and has therefore been redesignated IL-24 (2, 4–9). Several independent studies have demonstrated that a majority of human cancer-derived cell lines, including melanoma, prostate, breast, cervical, lung, fibrosarcoma, pancreatic, colorectal, and glioblastoma undergo apoptosis when exposed to mda-7/IL-24 (reviewed in Ref. 6). Current studies indicate that the mechanism by which mda-7/IL-24 induces cancer-specific apoptosis-inducing activity is complex, involving multiple signal transduction pathways and intracellular molecules (reviewed in Refs. 6, 10, 11), requiring further clarification.

The mRNA encoding mda-7/IL-24 is ~2 kb and encodes a protein predicted to have a molecular weight of M, 23,800 (2) belonging to the four-helix bundle family of cytokine molecules (8, 9). The open reading frame encodes a molecule that is 206-amino acids in length, which is a precursor form of the ultimate cleaved, post-translationally processed and secreted mature product. Three consensus asparagine glycosylation residues that are N-glycosylated, resulting in a mature secreted product showing multiple bands on denaturing protein gel electrophoresis likely because of partial and complete sugar modification on available sites (6, 10). The precursor form of mda-7/IL-24 is cleaved at position 48, the signal peptide cleavage recognition site, during import into the endoplasmic reticulum (ER) for processing and secretion via passage through the Golgi apparatus and secretory vesicles. The cleaved unprocessed protein has a predicted molecular weight of M, 18,200, and several groups have currently demonstrated processing and secretion of the molecule as predicted by the presence of consensus sites relevant to specific processing events (6, 10).

The present studies were designed to assess the relevance of mda-7/IL-24 secretion in mediating cancer gene therapy relevant biological effects (i.e., cancer-selective cell killing). Our results confirm that signaling events leading to susceptibility to Ad.mda-7- or Ad.SP mda-7-induced apoptosis have a potent intracellular mode of action and that this molecule is active in inducing transformed cell-specific apoptosis even without secretion. Our results also demonstrate significant involvement of extracellular signal-regulated kinase 1/2 (ERK1/2) in mda-7/IL-24-induced transformed cells-specific killing as one of several components potentially contributing to this observed activity.

Materials and Methods

Cell Lines, Adenoviruses, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Viability Assay, Fluorescence-Activated Cell Sorter Analysis, and Cell Counting. All human cancer cell lines were obtained from the American Type Culture Collection (Rockville, MD) other than the human fibrosarcoma 2T3GH and its derivatives, which were a kind gift from Dr. George Stark (Cleveland Clinic, Cleveland, OH). The immortalized normal prostate epithelial cell P69 was provided by Dr. J. Ware (Medical College of Virginia, Richmond, VA). Culture and maintenance of cells and construction, propagation, and utilization of adenoviruses were as described previously (12). Protocols used for MTT, fluorescence-activated cell sorting, and cell counts were as described previously (12).

Western Blot Analysis. Cell lines were grown on 10-cm plates and protein extracts were prepared with radioimmunoprecipitation assay buffer containing a mixture of protease inhibitors. Fifty μg of protein was applied to 12% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with polyclonal antibodies to mda-7, phospho-ERK1/2, and total ERK antibodies (12).

Matrigel Invasion Assay. Invasion of C8161 cells in vitro was measured as the capacity of cells to pass through a Matrigel-coated transwell insert (Corning Inc., NY). Briefly, transwell inserts with 8-μm pores were coated.
with Matrigel (1 mg/ml), cells were trypsinized, and 200-μl aliquots of cell suspension (1 × 10⁶ cells/ml) were added in triplicate wells. After 48-h incubation, cells that passed through the filter into the lower wells were quantified by direct counting.

**Bystander Tumor Growth Inhibition Assay.** The lower basal layer of cells (P69) was seeded at 2 × 10⁶ cells/cm² on 6-cm dishes and infected at 25 multiplicity of infection with the respective viruses. After 24 h, cells were washed five times with PBS and overlaid with 6 ml of 0.4% Noble agar containing 1 × 10⁵ DU-145 cells. After 14 days of incubation during which overlay cells were refed every 4 days, macroscopic colonies ≥2 mm were scored. Colonies were enumerated from triplicate plates, and values were expressed as an average ±SD.

**Immunofluorescence.** DU-145 and P69 cells were grown in chamber slides (Falcon; BD Biosciences, San Jose, CA) fixed with 2% paraformaldehyde, permeabilized with 0.1% Triton X-100, and then incubated with primary antibodies (antibody mAb-7). GM130 (BD Pharmingen, San Diego, CA), lysosome-associated membrane glycoprotein 1/2 (LAMP1/2; Santa Cruz, CA), calreticulin (BD Pharmingen), and Mitotracker marker (Molecular Probes, Eugene OR, FITC-conjugated donkey anti-rabbit IgG or anti-mouse IgG (Molecular Probes) were used for visualization on a Zeiss LSM 510 fluorescence microscope.

**Results**

**Growth Inhibitory Effect of Ad.Imda-7 and Ad.SP’mda-7 on Prostate Cancer Cell Lines.** Experiments were performed to determine whether infection with an adenovirus vector expressing a non-secreted version of MDA-7/IL-24 protein deleted for the signal peptide (Ad.SP’mda-7) could induce growth suppression and apoptosis in prostate tumor cells in a manner analogous to that observed using a full-length mda-7/IL-24 (Ad.Imda-7; Refs. 13, 14). Parallel experiments were performed with a normal immortalized untransformed prostate epithelial cell line (P69; Ref. 15) to define potential differential susceptibility to these viruses. These experiments confirmed that infection with both viruses induced comparable killing in susceptible prostate tumor cell lines (PC-3, DU-145, and LNCaP), but as previously reported, using Ad.Imda-7 (13) did not affect the viability of P69 cells (Fig. 1A).

Ad.Imda-7 or Ad.SP’mda-7 infection induced an increase in the proportion of DU-145 cells undergoing apoptosis as reflected by an increase in the proportion of cells with a sub-G₀/G₁ hypodiploid (A₀) DNA content (Fig. 1B), as previously described for Ad.mda-7-13). Similar results were obtained when LNCaP or PC-3 prostate tumor cells were infected with the two mda-7/IL-24 expressing adenoviruses (data not shown). In contrast, no significant change was observed in the percentage of apoptotic cells after infection of P69 cells with Ad.vec, Ad.SP’mda-7, or Ad.Imda-7 (Fig. 1B). This data provides further support for equivalent cancer-specific cell killing with Ad.Imda-7 or Ad.SP’mda-7.

To determine the extent of secretion of MDA-7/IL-24 protein after infection with Ad.SP’mda-7 and compare it with wild-type Ad.Imda-7, we analyzed the supernatant and pellets of infected cells by Western blotting 24 h after infection (Fig. 1C). Intracellular protein was observed in DU-145 cells in extracts derived from both Ad.SP’mda-7 and Ad.Imda-7. Secreted MDA-7/IL-24 protein was found in the supernatants only from Ad.Imda-7-infected cell lines at 24 h (as well as 48 and 72 h; data not shown). The intracellular fractions of mda-7/IL-24 expressed by Ad.SP’mda-7 differed from wild-type Ad.Imda-7-expressed protein in that the only band present in both extracts was a lower molecular weight band of ~M₈ 18,000. The additional higher molecular weight bands seen in the intracellular Ad.Imda-7 lane (Fig. 1C) are likely the previously reported posttranslationally processed forms of this molecule (16–18). This strengthens the possibility that absence of signal peptide impacts on further post-translational processing of the mutant protein, including lack of secretion. Because in both cases the killing effect is comparable, it is possible that the active form of protein does not necessarily require processing but might need localization to ER and Golgi compartments of cells to be functional. We have also noted an apparently lower amount of MDA-7/IL-24 protein expression, by Western blotting (Fig. 1C, left panel) with the Ad.SP’mda-7 virus compared with Ad.Imda-7. The viral titers used in these studies are equivalent, as is the extent of cell killing (Fig. 1, A and B). It is possible that (a) stronger intensity generated by glycosylated protein bands attributable to additional antibody trapping of primary or secondary antibody on sugar residues produces an apparently stronger signal for a given amount of protein compared with unglycosylated molecules (b) lower stability of unglycosylated MDA-7 protein because the sugar modification might contribute to stability results in an overall lower steady-state level of this form of protein. The amount of mda-7/IL-24 mRNA expressed by both viruses is comparable in Northern blot analyses. Regardless, the phenotypic effect of these two viruses irrespective of the apparent differences in protein expression level is essentially identical with respect to growth inhibition and apoptosis induction.

We previously demonstrated activation of ERK1/2 in glioblastoma cells upon Ad.mda-7 infection (19). To define whether ERK1/2 activation also plays a role in mda-7/IL-24-induced killing in prostate cancer cell lines we used PD98059, a specific mitogen-activated protein kinase kinase 1 signal pathway inhibitor (19). This pharmacological agent inhibited killing of DU-145 cells to a comparable extent after infection with either Ad.SP’mda-7 or Ad.Imda-7, whereas a similar experimental protocol did not affect the viability of P69 cells (Fig. 1D). A similar inhibition in cell killing was also apparent in PD98059-treated LNCaP and PC-3 cells infected with both viruses (data not shown). To further substantiate this observation, lysates of P69 and DU-145 cells, either uninfected or infected with the Ad.SP’mda-7 or Ad.Imda-7 virus, were analyzed by SDS-PAGE followed by Western blotting with antiphospho-ERK1/2 and anti-ERK (total) antibodies. As shown in Fig. 1D, treatment with Ad.SP’mda-7 or Ad.Imda-7 promoted ERK1/2 phosphorylation in prostate cancer cell lines, but not in the P69 cell line, correlating cell killing with activation of the ERK1/2 pathway. As documented previously for Ad.Imda-7 (12), we observed that the Ad.SP’mda-7 virus was capable of inducing apoptosis in cells functionally deficient for Jun-activated kinase/signal transducers and activators of transcription (JAK/STAT) signaling (Ref. 20; data not shown), further indicating functional equivalence.

**Secreted and Nonsecreted Forms of mda-7/IL-24 Inhibit Tumor Cell Invasion.** An additional comparison of the relative potencies of both forms of MDA-7/IL-24 protein focused on their impact on tumor cell invasiveness. For this analysis, the effect of Ad.SP’mda-7 and Ad.Imda-7 infection on the invasiveness of C8161 cells (metastatic human melanoma cells) was studied. This cell line was chosen because of its well-documented and reproducible invasive capacity in vitro as well as its tumorogenic and metastatic properties in the nude mouse assays 

References:

M. Seume and P. B. Fisher, unpublished data.
growth in monolayer culture (Fig. 2A, bottom panel), thereby confirming that invasiveness was not inhibited because of loss of cell viability. These results show that both constructs inhibit invasion with equivalent potency, providing yet another illustration of similar biological activity of these molecules.

Only the Secreted Form of mda-7/IL-24 Displays “Bystander” Antitumor Activity. Earlier studies in pancreatic cancer cells indicated that MDA-7/IL-24 protein possessed a potent bystander killing activity that exerted growth suppressive and apoptotic effects on nontransduced neighboring tumor cells (23, 24). To determine the extent of bystander...
APOPOTIC INDUCTION VIA mda-7/IL-24

increased the size of colonies growing in the agar overlay as compared with cells infected with Ad.vec. These studies provide direct support for a role of secreted MDA-7/IL-24 in mediating a "bystander" cancer growth-inhibitory effect.

Localization of MDA-7/IL-24 to ER/Golgi Compartments. In view of comparable apoptotic induction obtained with Ad.SP mda-7 versus Ad.mda-7, it was important to determine the location of the signal peptide-deleted MDA-7/IL-24 protein. Therefore, comparative subcellular localization of MDA-7/IL-24 protein was analyzed in DU-145 and P69 cells after infection with the Ad.SP mda-7 and Ad.mda-7 viruses. In these experiments, immunofluorescence detection was standardized at different time points to determine whether postinfection time-dependent changes in localization occurred. We also tried to avoid potentially misleading changes in localization that might occur as a result of the loss of internal membrane integrity because of apoptotic events induced by mda-7/IL-24. Comparison of the immunofluorescence data using different batches of viruses, cells and secondary antibodies performed at independent times, yielded similar reproducible patterns of staining with both viruses; representative data are presented for DU-145 in Fig. 3. Similar localization results were seen with P69 cells (data not shown). MDA-7/IL-24 protein was detected only in extra-nuclear regions of individual cells. Although there was a light background cytoplasmic staining, protein location primarily overlapped that of the ER stained with anticalreticulin (Fig. 3). The colocalization of MDA-7/IL-24 in Golgi apparatus was also detected via colocalization with anti-GLYCO30 staining (Ref. 25; Fig. 3). However, no co-localization of MDA-7/IL-24 in mitochondria labeled with MitoTracker red occurred (Ref. 26; Fig. 3) confirming staining specificity.

Discussion

On the basis of a number of factors, including its abilities to selectively induce apoptosis in a large spectrum of human cancer-derived cell lines without harming normal cells (reviewed in Ref. 6), inhibitory effects on the growth of human cancer cell xenographs in nude mice (23, 27), and most importantly its capacity to induce tumor regression after intratumoral injection in human tumors in currently ongoing clinical trials (28, 29), the likelihood of mda-7/IL-24 becoming a mainstream cancer gene therapeutic appears highly probable (6, 30). Consequently, considerable interest now exists in elucidating the mechanism by which mda-7/IL-24 distinguishes between normal and transformed cells. Just how mda-7/IL-24 induces this selective effect is clearly very complex, as underscored by experiments described in this manuscript and elsewhere (12) showing that the molecule can function independently of JAK/STAT signal transduction pathways that are classically involved in cytokine-mediated activities. We have additionally demonstrated by sensitive reverse transcription-PCR methodology that apoptosis can be induced in tumor cells not expressing detectable levels of IL-20/IL-22 receptors that bind to MDA-7/IL-24 (12).

The next logical step in pursuing our initial findings of JAK/STAT independence and potential lack of requirement of receptor binding for the antitransformed cell activity of mda-7/IL-24 (12) was to determine whether the apoptotic effect could be triggered by intracellular fractions (possibly by receptor-independent mechanisms) or if extracellular MDA-7/IL-24 protein (receptor mediated) was mandatory for activity. To achieve this objective, an adenovirus vector was constructed that expresses a nonsecreted version of MDA-7/IL-24 protein by deleting the 48 amino acid signal peptide, and the extent of killing, signal transduction pathway activation, intracellular localization, invasiveness, and bystander growth-inhibitory activity was compared with the full-length mda-7/IL-24. Although most of the analyses

activity, if any, by the nonsecreted mutant form of the protein versus the secreted form of MDA-7/IL-24, a dual cell culture agar overlay approach was used. For this protocol, P69 cells that are resistant to killing by MDA-7/IL-24, although serving as a source of production of this cytokine, were infected with the different viruses followed by overlaying with agar containing susceptible DU-145 cells (Fig. 2B). Using this strategy, infection of P69 cells with Ad.mda-7 (25 pfu/cell) resulted in a reduction in both the number and size of DU-145 colonies growing in agar. In contrast, infection of P69 cells with Ad.SP mda-7 did not induce a significant alteration in DU-145 anchorage independence nor did it decrease the size of colonies growing in the agar overlay as compared with cells infected with Ad.vec. These studies provide direct support for a role of secreted MDA-7/IL-24 in mediating a "bystander" cancer growth-inhibitory effect.

Localization of MDA-7/IL-24 to ER/Golgi Compartments. In view of comparable apoptotic induction obtained with Ad.SP mda-7 versus Ad.mda-7, it was important to determine the location of the signal peptide-deleted MDA-7/IL-24 protein. Therefore, comparative subcellular localization of MDA-7/IL-24 protein was analyzed in DU-145 and P69 cells after infection with the Ad.SP mda-7 and Ad.mda-7 viruses. In these experiments, immunofluorescence detection was standardized at different time points to determine whether postinfection time-dependent changes in localization occurred. We also tried to avoid potentially misleading changes in localization that might occur as a result of the loss of internal membrane integrity because of apoptotic events induced by mda-7/IL-24. Comparison of the immunofluorescence data using different batches of viruses, cells and secondary antibodies performed at independent times, yielded similar reproducible patterns of staining with both viruses; representative data are presented for DU-145 in Fig. 3. Similar localization results were seen with P69 cells (data not shown). MDA-7/IL-24 protein was detected only in extra-nuclear regions of individual cells. Although there was a light background cytoplasmic staining, protein location primarily overlapped that of the ER stained with anticalreticulin (Fig. 3). The colocalization of MDA-7/IL-24 in Golgi apparatus was also detected via colocalization with anticalreticulin (Ref. 25; Fig. 3). However, no co-localization of MDA-7/IL-24 in mitochondria labeled with MitoTracker red occurred (Ref. 26; Fig. 3) confirming staining specificity.

Discussion

On the basis of a number of factors, including its abilities to selectively induce apoptosis in a large spectrum of human cancer-derived cell lines without harming normal cells (reviewed in Ref. 6), inhibitory effects on the growth of human cancer cell xenographs in nude mice (23, 27), and most importantly its capacity to induce tumor regression after intratumoral injection in human tumors in currently ongoing clinical trials (28, 29), the likelihood of mda-7/IL-24 becoming a mainstream cancer gene therapeutic appears highly probable (6, 30). Consequently, considerable interest now exists in elucidating the mechanism by which mda-7/IL-24 distinguishes between normal and transformed cells. Just how mda-7/IL-24 induces this selective effect is clearly very complex, as underscored by experiments described in this manuscript and elsewhere (12) showing that the molecule can function independently of JAK/STAT signal transduction pathways that are classically involved in cytokine-mediated activities. We have additionally demonstrated by sensitive reverse transcription-PCR methodology that apoptosis can be induced in tumor cells not expressing detectable levels of IL-20/IL-22 receptors that bind to MDA-7/IL-24 (12).

The next logical step in pursuing our initial findings of JAK/STAT independence and potential lack of requirement of receptor binding for the antitransformed cell activity of mda-7/IL-24 (12) was to determine whether the apoptotic effect could be triggered by intracellular fractions (possibly by receptor-independent mechanisms) or if extracellular MDA-7/IL-24 protein (receptor mediated) was mandatory for activity. To achieve this objective, an adenovirus vector was constructed that expresses a nonsecreted version of MDA-7/IL-24 protein by deleting the 48 amino acid signal peptide, and the extent of killing, signal transduction pathway activation, intracellular localization, invasiveness, and bystander growth-inhibitory activity was compared with the full-length mda-7/IL-24. Although most of the analyses
were performed in human prostate cell lines, additional studies using a spectrum of cancer and normal cell lines, suggest that these observations are equally applicable to other human cancers.

The results presented here provide several independent lines of evidence indicating that the effect of Ad.SP mda-7 and Ad.mda-7 infection is similar with respect to transformed cell apoptosis induction. In particular, treatment of susceptible prostate cancer cell lines with Ad.mda-7 as well as Ad.SP mda-7 induces killing to a comparable extent through ERK1/2-dependent and JAK/STAT-independent pathways. The fact that both secreted and nonsecreted forms of MDA-7/IL-24 protein have comparable apoptosis-inducing activity was unanticipated, adding a further level of complexity in understanding how this novel molecule works. Localization of full-length MDA-7/IL-24 protein in the ER/Golgi compartments is consistent with the signal peptide hypothesis (31) and the currently known and predicted secreted cytokine nature of the protein (6, 10). Because the signal-peptidless mutant MDA-7/IL-24 protein does not contain an export signal, it is predicted to remain in the cytosol. We have, however, confirmed through confocal immunofluorescence studies that a significant fraction of this protein is able to enter the ER and Golgi apparatus and that proteins derived from wild-type and mutant virus appear to have overlapping patterns of localization within the cell. It is not possible to rule out cryptic internalization signals, which become active in the absence of the actual signal peptide, identity of these cryptic sites being currently unknown. Western blot analyses performed on protein-derived cytosolic and extracellular fractions of cells infected with both viruses indicate that only full-length MDA-7/IL-24 is processed and secreted. It is also possible that adenovirus infection produces relatively large amounts of protein that even in the absence of a specific targeting sequence possesses the ability to cross membranes and accumulate in ER/Golgi because of charge and/or tertiary structure. However, because localization of MDA-7/IL-24 is similar in both normal (P69; data not shown) and cancer (DU-145; Fig. 3) cells, differences in cellular localization of this protein can be excluded as a direct mechanism underlying the differential apoptosis-inducing activity of MDA-7/IL-24 toward cancer cells.

From the mechanistic, apoptosis-induction standpoint, programmed cell death pathways are activated by a diverse array of cell extrinsic and intrinsic signals, most of which are ultimately coupled to an obligatory signal propagation event mediated through mitochondria. In the context of localization of MDA-7/IL-24 to the ER/Golgi, emerging evidence suggests that the ER also regulates apoptosis by sensitizing mitochondria to a variety of extrinsic and intrinsic death stimuli and by initiating cell death signals of its own (32, 33). The observations presented here, raise the question, based on its apparent propensity for ER localization, whether MDA-7/IL-24 protein induces a recent recognition phenomenon of “ER-stress” that in turn induces proapoptotic events (32, 33). Earlier findings from our group support this hypothesis because induction of the GADD genes is classically associated with the stress response including ER-stress pathways. Induction of GADD genes and further upstream events such as activation of p38 mitogen-activated protein kinase was shown to be induced in a transformed cell-specific manner after Ad.mda-7 infection (34). In addition, we show in the present report that both viruses only in the context of transformed cells also specifically activate the p44/42 mitogen-activated protein kinase pathway. Furthermore, Ad.mda-7 infection produced an up-regulation in inositol 1,4,5-trisphosphate receptor in H295R cells (25). Inositol 1,4,5-trisphosphate receptor is an intracellular calcium-release channel implicated in apoptosis and localized in the ER. Whereas further investigations to determine the mechanism of specificity of MDA-7/IL-24 triggered ER-stress are clearly needed, this report for the first time identifies the existence of a cellular ER-stress mechanism that can be differentially activated in transformed cells by MDA-7/IL-24 and possibly other agents. This finding uncovers a new intracellular locus that may prove amenable for potential cancer therapeutic targeting.

Taken together, our results indicate that mda-7/IL-24-mediated apoptosis can be triggered through intracellular localization as well as via secretion, and in contexts where both are present, a combinatorial effect is probable. Our results, outlined in a model (Fig. 4), clearly reveal that nonsecreted intracellular MDA-7/IL-24 is also active in inducing transformed cell-specific apoptosis, probably through mechanisms mediated by the signaling pathways transduced through the
ER and Golgi compartments. These newer findings are provocative, although enigmatic, and indicate that much still remains to be learned about the mechanism of action of mda-7/IL-24, both in relation to its cancer-selective killing properties and to its potential immune modulatory functions (6, 30). However, based on the initial successes of this cytokine in phase I/II clinical studies in solid cancers and melanomas (28), this effort is certainly justified and holds promise for developing ways of enhancing the clinical utility of this novel cancer-gene therapeutic in treating diverse human neoplasms (6, 36).

Acknowledgments

We thank Peter Scheiffele, Columbia University, for the confocal microscopy studies and Nikolaq Yoshida for technical assistance. Confocal studies were performed at the Optical Microscopy Facility, a core facility of the Herbert Irving Comprehensive Cancer Center with the technical assistance of Sudhinda R. Swamy.

References

33. Pahl HL. Signal transduction from the endoplasmic reticulum to the nucleus.
Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein

Moira Sauane1,5, Rahul V Gopalkrishnan1,5, Heng-tong Choo1, Pankaj Gupta1, Irina V Lebedeva1, Adly Yacoub2, Paul Dent1 and Paul B Fisher*1,3,4

1Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA; 2Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA 23298, USA; 3Department of Neurosurgery, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA; 4Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, College of Physicians and Surgeons, New York, NY 10032, USA

The human mda-7/IL-24 gene product is normally expressed in melanocytes and certain lymphocyte populations. Loss of expression, a distinctive feature of many tumor suppressor genes, has been documented at RNA and protein levels in association with melanoma progression both in vitro as well as in human tumor-derived material. The MDA-7/IL-24 protein undergoes post-translational processing, including removal of an amino-terminal 48-residue signal peptide and extensive glycosylation prior to its secretion by producing cells. Its inherent cytokine properties have been documented in multiple reports, which have identified and characterized its cognate receptors and activation of the JAK/STAT signaling pathway following ligand/receptor docking. A notable and incompletely understood property of MDA-7/IL-24 is its ability to induce apoptosis in transformed cells, while having marginal growth suppressive effects on normal primary or immortalized cell lines. MDA-7/IL-24 has been delivered to cells, tumor xenografts and patients in clinical trials via a nonreplicating adenovirus (Ad.mda-7). Studies utilizing eukaryotically expressed and purified MDA-7/IL-24 protein from several sources have recapitulated some of the molecule's reported properties including receptor binding and JAK/STAT activation. Here, we report the properties and characteristics of a bacterially expressed and purified GST-MDA-7 fusion protein. These studies reveal that GST-MDA-7 retains its cancer-selective apoptosis-inducing properties, thereby providing a new reagent that will assist in defining the mechanism of action of this novel cytokine. In addition, retention of tumor-specific activity of GST-MDA-7 suggests that this protein may also have therapeutic applications.

Published online 30 August 2004

Keywords: cancer gene therapy; GST-MDA-7/IL-24; apoptosis; breast cancer; radiotherapy

Introduction

mda-7/IL-24 displays all the characteristics of a typical cytokine including secretion, receptor binding, activation of JAK/STAT signaling and modulation of growth characteristics of responsive cells (Huang et al., 2001; Caudell et al., 2002; Sauane et al., 2003b). This molecule was initially discovered using a differential gene expression subtraction screening strategy to identify and clone genes upregulated during melanoma cell differentiation (Jiang and Fisher, 1993; Jiang et al., 1995). Owing to no obvious homology to sequences in public databases, it was initially not apparent that mda-7 was a cytokine-related molecule. Currently, in addition to biochemical data demonstrating secretion and cytokine properties, location of mda-7/IL-24 in an IL-10 family-related genomic cluster on human chromosome 1q22/1q23 has emphasized its actual functional identity (Blumberg et al., 2001; Huang et al., 2001). Thus, the recently recognized IL-10 family comprises six members including IL-10, IL-19, IL-20, IL-22, mda-7/IL-24 and IL-26 (Gallagher et al., 2000; Blumberg et al., 2001; Pestka et al., 2004), none of which share significant homology at the primary amino acid level, but which clearly possess functional and structural conservation justifying their subclassification as a distinct cytokine subfamily. Recent work has focused on determining the actual physiological roles of each molecule and the extent of their functional overlap or distinctiveness (Caudell et al., 2002; Fickenscher et al., 2002; Kisseleva et al., 2002; Kostenko, 2002; Parrish-Novak et al., 2002; Sarkar et al., 2002a; Pestka et al., 2003, 2004; Sauane et al., 2003b).

A unique property of mda-7/IL-24 is its ability to induce apoptosis specifically in transformed cells while having no apparent harmful effect on normal counterparts, including normal human tissues in vivo clinical trial contexts (Jiang et al., 1996a; Su et al., 1998; Madiredla et al., 2000; Sucki et al., 2000; Chada et al., 2001; Huang et al., 2001; Lebedeva et al., 2002; Sarkar et al., 2002b; Fisher et al., 2003; Nemnicht, 2003). This unique property is under intense scrutiny from the viewpoint of mechanism of tumor cell specificity to more effectively translate mda-7/IL-24 from the laboratory into the clinic as a cancer gene therapeutic (Chada et al., 2001; Fisher et al., 2003;...
Nemunita, 2003). Various reagents have been raised to address the functional activity and transformed cellspecificity of mda-7/IL-24 including an adenovirus (Jiang et al., 1996b) used in clinical trials as well as plasmid expression vectors (Jiang et al., 1995, 1996b), antibodies and various forms of purified protein utilized in the laboratory (Caudell et al., 2002; Parrish-Novak et al., 2002; Ramesh et al., 2003; Yacoub et al., 2003a, 2004).

Schistosoma japonicum derived Glutathione-S-transferase (GST)-tagged fusion proteins have several favorable attributes that facilitate protein expression and purification that are not achievable for proteins expressed in untagged native form (Smith and Johnson, 1988; Zhan et al., 2001). Fusions can be easily expressed in the Escherichia coli system with high yield and this approach has been effective for a wide range of biologically active peptides or proteins, without disrupting their native activity (Zhan et al., 2001). Recent data indicate that GST has high transduction efficiency in various cell types and can be used successfully for intracellular delivery of biologically active peptides (Namiki et al., 2003). A GST-MDA-7 fusion protein was expressed and purified from a bacterial expression system to generate antigen for producing antibodies recognizing MDA-7/IL-24 protein. In the course of these experiments, analysis was also performed to determine if this purified protein had biological activity. These studies which are described in the following sections, contrasts with reports of activity of purified MDA-7/IL-24 protein expressed and purified by three independent groups using other expression systems (Caudell et al., 2002; Parrish-Novak et al., 2002; Ramesh et al., 2003). Our results confirm that signaling events leading to susceptibility to GST-MDA-7-induced apoptosis are phosphatidylinositol-dependent in transformed cell-specific killing. Data reported here indicate that GSTMDA-7 is taken up by cells and can internalize. Moreover, all pancreatic cancer cells tested with GST-MDA-7 protein are directly susceptible to killing, whereas these cells display resistance to killing following infection by Ad.mda-7 (Su et al., 2001). In these contexts, the GST-MDA-7 fusion protein provides a valuable reagent for analysing the molecular basis of cancer-specific apoptosis-inducing properties of this novel molecule, which previously was a property restricted to delivery by adenoviral expression vectors. In addition, the ability of GST-MDA-7 to induce cancer cell killing in specific cancer cells, whereas adenovirus mediated mda-7/IL-24 does not induce this property, offers potential to increase the therapeutic efficacy of this intriguing clinically relevant cytokine.

Results

GST-MDA-7 fusion protein displays cancer cell-killing specificity and is able to distinguish between transformed and normal cells

The immortalized prostate epithelial cell line P69 and the prostate tumor cell line DU-145 were treated under identical conditions to determine the effect and specificity of GST-MDA-7 protein. After determining the appropriate range of protein needed for activity (data not shown), cells were treated with a predetermined optimum protein concentration (50 ng/μl) and observed 24 h until cytotoxicity was apparent, which occurred between 48 and 72 h post-treatment compared to cells treated with unfused control GST protein (Figure 1a). Minimal or no cytotoxicity was observed in GST treated normal- or tumor-derived cells. In comparison, significant cell killing was evident in the human prostate cancer cell line, DU-145, after treatment with GST-MDA-7 protein, which had little effect on resistant P69 cells. From these results, it appears that the bacterially derived protein has comparable properties, in terms of cancer cell-specificity, to protein derived from Ad.mda-7.

To confirm that the observed cell killing, following treatment with GST-MDA-7 resulted from induction of apoptosis, FACS analysis was performed on susceptible DU-145 prostate cancer and resistant P69 cells. Cells were treated in parallel with GST and GST-MDA-7 protein at 50 ng/μl after plating at 2 x 10⁵ cells/6-cm dish utilizing one plate for each time point. Samples were withdrawn at various time points and fixed in 80% ethanol after trypsinization. Cells were stained with propidium iodiode and FACS analysis was performed to determine the proportion of apoptotic cells in the population as a function of time (Figure 1b and c). Treatment of P69 cells up to 96 h with GST-MDA-7 gave a similar FACS profile as untreated or GST control treated cells (Figure 1b), while DU-145 treated cells showed a 50% A₁, population at 96 h compared to less than 21% for untreated and GST-treated populations (Figure 1c). The extent of cell killing is likely underestimated since a certain proportion of cells were highly fragmented or lysed following GST-MDA-7 treatment and could not be analysed by FACS. A certain proportion of dead cells were observed in the untreated and GST-treated samples at later time points due to confluence and cell overgrowth. These data indicated that susceptible cells treated with GST-MDA-7 undergo apoptotic death.

Annexin V staining was performed on susceptible prostate cancer cell lines and resistant normal immortal P69 cells. Annexin V staining confirmed increases in early apoptotic cells (24 h) as a function of GST-MDA-7 treatment in PC-3, DU-145 and LNCaP cells (Figure 1d). In contrast, no significant change in early apoptotic cells was apparent in P69 cells using the same experimental protocol.

GST-MDA-7 induces apoptosis in mutant cell lines defective in the JAKSTAT pathway

We investigated the specific requirements of the JAK/STAT pathway in GST-MDA-7-mediated killing by employing cell lines functionally deficient for JAK/STAT. These included a human fibrosarcoma cell line 2F TGH (parental) and corresponding mutant cell lines derived from it, including U1A (lacking Tyk2), U3A (IFN-unresponsive, lacking STAT1), and U4A (lacking
JAK1). The human prostate cancer cell PC-3, that does not express STAT3 (Spiotto and Chung, 2000) was used to complete the known spectrum of mda-7/IL-24-mediated pathway components. These cell lines were treated with GST-MDA-7 and viability was analysed by using an MTT cell proliferation assay. In addition, two inhibitors of tyrosine kinases, Genistein and tyrophostin AG18 as well as the JAK-selective inhibitor, AG490, were utilized (Sauane et al., 2003a). All of these cell lines were susceptible to GST-MDA-7 (Figure 2a, compare GST to GST-MDA-7). These data provide an independent means of confirmation that the activation of JAK/STAT induced by mda-7/IL-24 can be separated from cell apoptosis induced after GST-MDA-7 treatment, since the cells tested have inactivating mutations in JAK/STAT signaling components. DU-145 cells were also treated with GST-MDA-7 protein during different periods of time and analysed for activation of the JAK/STAT pathway by determining the extent of STAT3 phosphorylation. As evident in Figure 2b, treatment with purified GST-MDA-7 protein does not induce phosphorylation of STAT3, whereas treatment with fibroblast interferon (1000 U/ml) induces a temporal induction of STAT3 phosphorylation.

**Cytotoxicity of bacterial GST-MDA-7 protein is inhibited by treatment of cells with the p38MAPK inhibitor SB203580**

As previously reported, inhibition of the p38MAPK pathway by pharmacological inhibitors or dominant-negative adenovirus blocked the ability of Ad.mda-7 to kill different cancer cell types, including PC-3 (Sarkar et al., 2002b). PC-3 human prostate cancer-derived cells were incubated in the absence or presence of SB203580 (2 μM), 24 h before treatment with GST or GST-MDA-7 protein and the extent of cytotoxicity was determined (Figure 3a and b). Under these experimental conditions, a significant inhibition of GST-MDA-7-induced killing of PC-3 prostate cancer cells was obtained following...
SB203580 treatment. These results indicate that GST-MDA-7 protein most probably acts in a comparable manner as Ad.mda-7 by activating the p38MAPK pathway as one of the potential pathways by which transformed cell-specific apoptosis is induced.

GST-MDA-7 protein is able to kill human pancreatic cancer cells in the absence of ablation of Ras signaling by antisense K-Ras.

We previously reported that human pancreatic cancer-derived cell lines are not susceptible to direct killing by Ad.mda-7 (100 PFU/cell) (Su et al., 2001). We further showed that lack of killing was due to absence or very low amount of MDA-7/IL-24 protein expression. Treatment of resistant cells with a combination of antisense K-ras (phosphothiorate oligonucleotides or a plasmid expressing this AS molecule) and Ad.mda-7 vector caused killing which correlated with reappearance of MDA-7 protein. We presently demonstrate that treatment of these resistant cells with purified GST-MDA-7 protein is able to induce cell death directly, strengthening the hypothesis that a translational block might be operational in these and additional MDA-7/
IL-24-resistant cells (Figure 4a). Since all of the pancreatic cancer cells treated with GST-MDA-7 protein, irrespective of their K-ras status, are directly susceptible to killing, it appears that cells or tumors that appear to be resistant to infection with Ad.mda-7, might still be killed following direct exposure to purified protein. This observation suggests added clinical significance in a resistant or uninfactible (by adenovirus) tumor context.

The human pancreatic cancer cell line BxPC-3 is completely resistant to killing by Ad.mda-7 either in the presence or absence of K-ras ablation (Su et al., 2001). This cell line is wild type for K-ras and does not express detectable levels of MDA-7 protein after combination treatment with antisense K-ras + Ad.mda-7. However, exposure of these cells to GST-MDA-7 protein results in cell killing, as shown in Figure 4. Treatment of BxPC-3 and other normal and cancer cell types (not shown) with bacterially expressed and purified GST-MOB-5, the rat orthologue of mda-7 (Wang et al., 2002), showed no cytocidal effects on cells and was comparable to treatment with unfused GST protein (Figure 4b). This protein derived from the rat sequence was also a bacterially expressed and purified GST fusion, which had no effect on cell viability under conditions where GST-MDA-7 caused a significant amount of cancer-specific cell death. Therefore, cancer-cell specificity of mda-7/IL-24 is further strengthened following parallel utilization of a closely related molecule mob-5 (~80% similar) derived from rat.

**Apoptosis induction by exogenously administered GST-MDA-7 protein is likely due to rapid uptake by cells**

DU-145 cells were treated with control GST or GST-MDA-7 fusion proteins following plating on coverslips. Cells were washed thoroughly with PBS to remove externally bound material before fixation. Parallel sets of samples were reacted with anti-GST and anti-MDA-7 antibody followed by Alexa Fluor 488 tagged secondary antibody for immunofluorescent detection of protein (Figure 5). Several time points were utilized to determine kinetics of protein uptake and additional controls including secondary antibody alone, and nonsusceptible FM-516-SV normal immortal human melanocytes were used in parallel (not shown). When analysed with anti-
GST antibody, both control GST protein as well as GST-MDA-7 were visualized inside cells in extranuclear locations. Samples processed in parallel, but reacted with anti-MDA-7 specific antibody, indicated an intracellular localization of GST-MDA-7 protein. Specificity is demonstrated due to lack of detection of protein in GST-treated samples reacted with anti-MDA-7 antibody. It therefore appears that both GST as well as

![Image](image_url)

**Figure 4** Comparative growth inhibition and apoptosis induction in pancreatic cancer cells treated with GST or GST-MDA-7. (a) Cells were treated with GST or GST-MDA-7 and cell viability was determined by the MTT proliferation assay 5-days later. Numbers represent a ratio of specific treatments versus untreated cells. An average of three independent experiments is shown ± s.d. (b) BxPC3 (wild-type K-ras) human pancreatic cancer cell line was plated in triplicate at 1 x 10^4 cells/6 cm dish. Surviving cells were counted 72 h after treatment with purified GST, GST-MDA-7, and GST-mob5 protein expressed and purified under identical conditions. Untreated cells (UT) were used as an additional control. Cell counts were performed using trypan blue dye exclusion to enumerate the number of surviving cells after treatment.

![Image](image_url)

**Figure 3** Effect of the p38MAPK inhibitor on GST-MDA-7-induced killing in prostate cancer cell lines. Cells were incubated in the absence or presence of SB203580 (2 μM) before treatment with GST or GST-MDA-7. (a) Photomicrograph demonstrating cytotoxicity of GST-MDA-7 and the ability of SB203580 to block this effect in PC-3 cells. (b) Effect of GST and GST-MDA-7 alone or in combination with SB203580 on growth of PC-3 cells. Cell viability was determined by MTT assay 5-days after infection. MTT absorbance of untreated control cells was set at 1 to determine relative number of viable cells. Results shown are an average of three independent experiments, ± s.d.
GST-MDA-7 fusion protein are internalized by cells. It is unclear if this is a receptor-mediated process though a more likely possibility is that the GST moiety facilitates uptake of protein by cells, as recently reported (Namiki et al., 2003).

**MDA-7/IL-24 localizes to the ER/Golgi compartments**

Based on previous results indicating that apoptosis induced by mda-7/IL-24 have a potent intracellular mode of action and this molecule is active in inducing transformed cell-specific apoptosis even without secretion (Sauane et al., 2004; Sieger et al., 2004), it was important to determine the subcellular location of GST-MDA-7 protein. Therefore, comparative subcellular localization of MDA-7/IL-24 was analysed in DU-145 cells after treatment with protein for 24 h. GST-MDA-7 protein was detected only in extra-nuclear regions of individual cells. While there was a light background cytoplasmic staining, protein location primarily overlapped that of the endoplasmic reticulum (ER) stained with anti-calreticulin. The colocalization of MDA-7/IL-24 in the Golgi apparatus was also detected via colocalization with anti-GM130 staining. However, no colocalization of MDA-7/IL-24 in mitochondria labeled with MitoTracker red occurred, confirming staining specificity in DU-145 cells (Figure 6). Similar localization results were obtained using the GST-MDA-7 protein in P69 cells, suggesting that differential localization of MDA-7 following treatment with this fusion protein may not be a contributing factor in determining the differential sensitivity of cancer versus normal cells to GST-MDA-7 (unpublished data).

**GST-MDA-7 protein is able to kill human breast cancer cells and it has radiosensitizing effects similar to Ad.mda-7**

Ionizing radiation has been shown to enhance the killing effect of purified GST-MDA-7 protein in glioma cells in vitro (Su et al., 2003; Yacoub et al., 2003b, 2004). To test whether GST-MDA-7 is able to induce a similar effect in breast cancer cells lines and whether radiation can modulate apoptosis, first MDA-MB-231 cells were treated with bacterially synthesized GST-MDA-7 at different concentrations to determine effect on cell growth. As shown in Figure 7a, GST-MDA-7, but not GST, induced a dose-dependent decrease in viability in MDA-MB-231 cells as reflected by MTT assay. MDA-MB-231 cells were treated with bacterially synthesized GST-MDA-7 followed by exposure to ionizing radiation (Figure 7b). GST-MDA-7 suppressed MDA-MB-231 cell growth that was enhanced in a greater than an additive fashion by ionizing radiation (Figure 7b). The direct growth inhibitory effect of purified protein in additional breast cancer cell lines was observed when MCF-7, T47D and MDA-MB-157 breast tumor cells were treated with the GST-MDA-7 protein (Figure 7c). In contrast, no significant change in viability or growth was observed following treatment of the normal HBL-100 breast epithelial cell line with GST-MDA-7 (Figure 7c). These data provide further support for equivalent cancer-specific cell killing when mda-7/IL-24 is applied to cells as a GST-MDA-7 fusion protein produced in bacteria. Moreover, cancer-cell specific killing in breast cancer cells by GST-MDA-7, as previously shown using Ad.mda-7 (Su et al., 1998), occurs in a p53-independent
manner, that is, MCF-7 (is wild-type p53), MDA-MB-157 (is null for p53), and MDA-MB-231 and T47D (are mutant for p53).

Discussion

Considerable interest exists in elucidating the mechanism by which mda-7/IL-24-mediated apoptosis differentiates between normal and transformed cells. Precisely, how mda-7/IL-24 induces this selective effect is clearly very complex and can vary in a cell-type and cancer-specific context (Sarkar et al., 2002a; Fisher et al., 2003; Sauane et al., 2003b). The antitumor cell activity of the molecule can function independently of JAK/STAT signal transduction pathways that are classically involved in cytokine-mediated activities, now documented using GST-MDA-7 protein as well as previously reported using adenoviral delivery of mda-7/IL-24 (Sauane et al., 2003a). Additionally, we previously demonstrated by sensitive RT-PCR methodology that apoptosis could be induced in tumor cells not expressing detectable levels of IL-20/IL-22 receptors that bind to MDA-7/IL-24 (Sauane et al., 2003a). Moreover, an adenovirus vector expressing a nonsecreted version of MDA-7/IL-24 protein was generated via deletion of its signal peptide, and this nonsecreted protein was as effective as wild-type secreted MDA-7/IL-24 in inducing apoptosis (Sauane et al., 2004), confirming that mda-7/IL-24-mediated apoptosis can be triggered through intracellular localization as well as via secretion. Our results and recent studies by others clearly reveal that intracellular MDA-7/IL-24 is active in inducing transformed cell-specific apoptosis, probably through mechanisms overlapping and possibly involving pathways associated with ER-stress or the unfolded protein response mechanism (Sauane et al., 2004; Sieger et al., 2004). Induction of GADD genes is classically associated with the stress response including ER-stress pathways. Induction of GADD genes and further upstream events such as activation of p38MAPK was shown to be induced in a transformed cell-specific...
manner after Ad.mda-7 infection (Sarkar et al., 2002b). Furthermore, Ad.mda-7 infection upregulated the inositol 1,4,5-trisphosphate receptor (IP3R) in H1299 cells (Mhashilkar et al., 2003). IP3R is an intracellular calcium-release channel implicated in apoptosis and localized in the ER. Finally, nonsecreted protein and wild-type secreted MDA-7/IL-24 localizes in the Golgi/ER compartments (Sauane et al., 2004), as does the bacterially expressed and purified GST-MDA-7 fusion protein.

Previous studies have documented that secreted MDA-7/IL-24 from supernatants of HEK 293 cells has biological activity. Specifically, in human PBMCs, MDA-7/IL-24 functions as a pro-Th1 cytokine and induces production of IFN-γ, IL-6, and tumor necrosis factor α (Caudell et al., 2002). MDA-7/IL-24 is also a potent antianiogenetic effector in vitro as well as in vivo (Ramesh et al., 2003). The studies listed above have likely utilized purified secreted native protein at relatively lower concentrations than achieved via Ad.mda-7 infection possibly due to limitations of the source of production (a stably transfected 293 cell line, Caudell et al., 2002). Purified MDA-7/IL-24 used in these studies was able to activate phosphorylation of STAT1/3. However, none of these studies, utilizing native secreted MDA-7/IL-24 demonstrated growth inhibition or apoptosis induction (Caudell et al., 2002; Ramesh et al., 2003; Parrish-Novak et al., 2002) demonstrated that in NIH:OVCAR-3, MDA-7/IL-24 inhibited cell growth only at doses above 600 pg/mL. This cytostatic effect employs an alternative pathway since STAT1/3 activation was not observed and the authors speculate that it probably occurs through nonclassical receptor activation or might be receptor independent. Further, this growth inhibitory activity was reversible. To try to dissect the pathways involved in the growth inhibitory activity of MDA-7/IL-24 using adenoviral delivery or via purified bacterial GST-fusion protein, it is clear that we need to distinguish between physiological and supraphysiological expression of MDA-7/IL-24 (Fisher et al., 2003). In the work by Caudell et al. (2002), treatment of primary human PMBCs with bacterial or yeast-derived protein required a relatively high amount of protein (μg/ml range) to elicit responses such as secretion of secondary cytokines (IL-6, TNF-α and IFN-γ) compared to subsequent studies described in the same report performed utilizing native MDA-7/IL-24 protein derived from tissue culture supernatants of a stably transfected cell line (Caudell et al., 2002). As mentioned above, purified MDA-7 derived-protein from tissue culture supernatant and others, including alternate bacterial (6-Histidine tagged) and baculovirally derived sources have demonstrated cytokine-related activity including receptor binding (Wang et al., 2002) and JAK/STAT activation but not transformed cell-specific killing that we have obtained with the GST-fusion described in this report. The reasons for the difference in activity are presently unclear, but might involve factors such as protein stabilization and internalization described below.

Experiments reported here have validated the equivalence of bacterially expressed GST-MDA-7 fusion and adenovirally expressed untagged MDA-7/IL-24 protein in terms of their selective antitumor properties. A significant number of reports of peptides or proteins has been successfully expressed as GST fusion proteins without losing their biological activity (Smith and Johnson,
Cancer gene therapy using Ad.mda-7 has significant promise and based on initial successes continues to be evaluated in Phase I/II clinical trials (Chada et al., 2001; Nemunaitis, 2003). The potential use of GST-MDA-7 protein as a therapeutic is intriguing, since it can enlarge the existing MDA-7/IL-24 therapeutic scope to cover tumors resistant to or uninflectable by Ad.mda-7. It is presently demonstrated that direct application of GST-MDA-7 can kill pancreatic cancer cell lines previously resistant to Ad.mda-7 (Figure 4). Another example is renal cell carcinoma (RCC), where recent studies demonstrated that Ad.mda-7 did not affect RCC proliferation due to weak infectivity, but GST-MDA-7 caused a dose-dependent growth suppression (Yacoub et al., 2003b, 2004). Additional work has demonstrated that both Ad.mda-7 as well as the GST-MDA-7 fusion protein is able to radiosensitize primary human glioblastoma cells to comparable extents (Su et al., 2003; Yacoub et al., 2003a, 2004). When analyzed with anti-GST antibody, both control GST protein as well as GST-MDA-7 is visualized inside cells in extranuclear locations. Samples processed in parallel but reacted with anti-MDA-7 antibody show an intracellular localization of GST-MDA-7 protein. Specificity is demonstrated due to lack of detection of protein in GST-treated samples reacted with anti-MDA-7 antibody. It therefore appears that GST as well as GST-MDA-7 fusion proteins are internalized by cells. It is unclear if this is a receptor-mediated process, although a more likely possibility is that the GST moiety facilitates uptake of protein by cells as recently reported (Namiki et al., 2003).

The retention of biological activity and particularly, cancer cell specificity of bacterially produced GST-MDA-7 was unexpected given the large size of the amino-terminally located tag and its likely interference in receptor binding. However, our recent findings that the mda-7/IL-24 gene functions efficiently in the absence of secretion following mutation of its signal peptide (Sauane et al., 2004) and the ability of GST-fusion proteins to enter cells could explain why GST-MDA-7 demonstrates cancer-cell-specific apoptosis inducing activity. In these contexts, the availability of this bioactive fusion protein allows for more detailed kinetic studies of MDA-7/IL-24 action, such as varying exposure time, which is difficult to achieve with Ad.mda-7. The purified active protein can provide an additional reagent of some utility in the ongoing analysis and characterization of mda-7/IL-24 as a potential cancer gene therapeutic. Accordingly, the observation that purified GST-MDA-7 protein is able to kill Ad.mda-7-resistant pancreatic cancer cells is particularly relevant. This indicates potential complementarity in utilization of two distinct reagents (Ad.mda-7 and GST-MDA-7) for analytical and therapeutic uses. Additionally, now having this unique combination of reagents in hand to deliver mda-7/IL-24 provides an unparalleled opportunity for defining the biochemical and molecular events controlling cancer-cell specificity of this clinically pertinent cytokine.
Materials and methods

Cell lines and culture conditions

PC-3, LNCaP and DU-145 (human prostate cancer), 2T GTH (human fibrosarcoma) and corresponding mutant sublines U1A, U3A, U4A and USA (Darrell et al., 1994) (kind gift of G Stark, Cleveland Clinic, OH, USA) were grown in Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12) supplemented with 10% FBS at 37°C in a humidified 5% CO2 incubator. Human prostate carcinoma cell lines (AsPC-1, BxPC-3, Mia PaCa-2, and Panc-1) were maintained in RPMI 1640 medium containing 10% FBS, antibiotics and l-glutamine (Blumberg et al., 2001). Normal human breast epithelial cells and human breast cancer-derived lines MCF-7, T47D, MDA-MB-231, and MDA-MB-157 were grown in DMEM containing 10% FBS.

Synthesis of GST-MDA-7

Standard cloning procedures were used to generate a bacterial expression vector comprising in-frame fusion of the mda-7/IL-24 open reading frame ‘3′ to the GST open reading frame in GST-T2 vector (Amersham Pharmacia, NJ, USA), using BamH1 and NotI sites introduced into the mda-7/IL-24 ORF by PCR. Expression of protein was performed by inoculating an overnight culture at 1:100 dilution followed by incubation at 25°C until an A600 of 0.4-0.6 was reached, followed by induction with 0.1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) for 2 h. Cells were harvested by centrifugation and sonicated in PBS followed by centrifugation to obtain soluble protein. The lysates were bound to a glutathione-agarose column (Amersham Pharmacia, NJ, USA) at 4°C for 2 h followed by washing with 50 volumes of PBS and 10 volumes of PBS with 500 mM NaCl. Passing 20 mM-reduced glutathione through the column and collecting 1 ml fractions performed elution of bound protein. Fractions were analysed by gel electrophoresis, and positive samples were dialysed against 1000 volumes of PBS for 4 h with one change, followed by 500 volumes of DMEM for 4 h. Protein concentration was estimated by Bradford assays, as well as gel electrophoresis, in conjunction with Coomassie blue staining. Samples were tested for activity using GST protein as control. An antipeptide, rabbit polyclonal antibody was raised to specifically detect MDA-7 protein and was used in these studies at 1:1000 dilution for immunoblotting and 1:200 dilution for immunofluorescence.

MTT assays

Cells were plated in 96-well dishes (1 x 10^4)/cell/well) in DMEM/F12 containing 10% FBS and allowed to attach for 12h prior to GST or GST-MDA-7 treatment, usually at 25-30 ng/ml. Treatment with inhibitors was initiated 1 h before treatment with protein. During a 5-7-day-treatment period, the medium was changed twice with fresh inhibitor containing medium at days 3 and 6. Cell growth and viable cell numbers were monitored by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) staining as described (Lebedeva et al., 2000, 2002). The resulting absorbance measured at 595 nm is directly proportional to the number of viable cells.

Annexin-V binding assay

Cells were trypsinized and washed once with complete media. Aliquots of the cells (5 x 10^6) were resuspended in complete medium (0.5 ml) and stained with FITC-labeled Annexin-V (kit from Oncogene Research Product, Boston, MA, USA) according to the manufacturer’s instructions. Propidium iodide (PI) was added to the samples after staining with Annexin-V to exclude late apoptotic and necrotic cells. The FACS assay was performed immediately after staining.

FACS analysis

Cells were trypsinized and washed once with complete media. Aliquots of cells (5 x 10^6) were resuspended in complete medium (0.5 ml). Propidium iodide (PI) was added to the samples. FACS assays were performed immediately after staining. The percentage of cells in the apoptotic (A+) fraction was calculated using CellQuest software (Becton Dickinson).

Western blot analyses

Cell lines were grown on 10-cm plates and protein extracts were prepared with RIPA buffer containing a cocktail of protease inhibitors. A total of 50 μg of protein was applied to 12% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with polyclonal antibodies to MDA-7/IL-24, phospho-STAT3 and total STAT3 (Cell Signalling Technology, MA, USA).

Immunofluorescence analyses

DU-145 cells were grown in chamber slides (Falcon-BD, CA, USA) fixed with 2% paraformaldehyde, permeabilized by 0.1% Triton X-100, and then incubated with primary antibodies: anti-rabbit mda-7, GM130 (BD Pharmingen, CA, USA), LAMP1/2(Santa Cruz, CA, USA), Calreticulin (BD Pharmingen, CA, USA) and Mitotracker marker (Molecular Probes, Eugene, OR, USA). FITC-conjugated donkey anti-mouse IgG and anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) were used for visualization on a Zeiss LSM 510 fluorescence microscope.

Acknowledgements

The present research was supported in part by National Institutes of Health Grants CA097318, CA88906, DK52825 and CA098172, DAMD-02-1-0041, the Samuel Waxman Cancer Research Foundation, the Lustgarten Foundation for Pancreatic Cancer Research and the Chernow Endowment. PB Fisher is the Michael and Stella Chernow Urological Cancer Research Scientist. M Sauane is the recipient of a DOD post-doctoral fellowship. We acknowledge NikoLaV Vozhilla for indispensable technical assistance and Sudhindra R Swamy of the optical microscopy facility of the Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center for assistance in confocal microscopy.

References


